TY  - CONF 
AU  - Calvo Martínez, Lourdes
AU  - García Mata, Jesús
AU  - López López, Rafael
AU  - Castellanos Diez, Javier
PY  - 2011
SN  - 0008-5472
UR  - http://hdl.handle.net/20.500.11940/2883
LA  - eng
TI  - Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)
DO  - 10.1158/0008-5472.SABCS11-P3-14-15
VL  - 71
ER  -